Valuation: ADIL PHARPAR

Market Cap 1.33Cr 1.19Cr 1.09Cr 98.98L 1.85Cr 125.91Cr 1.88Cr 13Cr 5.23Cr 66Cr 4.98Cr 4.87Cr 208.88Cr P/E 2026 *
-3.34x
P/E 2027 * -8.28x
Enterprise Value 1.33Cr 1.19Cr 1.09Cr 98.98L 1.85Cr 125.91Cr 1.88Cr 13Cr 5.23Cr 66Cr 4.98Cr 4.87Cr 208.88Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-21.93%
1 week+3.53%
Current month-4.99%
1 month-7.75%
3 months+14.07%
6 months+145.81%
Current year-30.73%
1 week 3.02
Extreme 3.02
5.15
1 month 3
Extreme 3
5.15
Current year 1.31
Extreme 1.31
7.2
1 year 1.31
Extreme 1.31
8.75
3 years 1.31
Extreme 1.31
104.25
5 years 1.31
Extreme 1.31
2,200
10 years 1.31
Extreme 1.31
5,900
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Free

Director

25,666 0.9774%
07/04/26 Free

Chief Financial Officer

17,325 1.2133%
07/04/26 Free

Chairman

9,185 0.6432%

Financials

2026 *2027 *
Net sales - -
Net income -6.55Cr -5.86Cr -5.39Cr -4.89Cr -9.13Cr -621.56Cr -9.3Cr -64Cr -26Cr -326.96Cr -25Cr -24Cr -1.03TCr -2.11Cr -1.89Cr -1.74Cr -1.58Cr -2.95Cr -200.7Cr -3Cr -21Cr -8.34Cr -105.58Cr -7.93Cr -7.76Cr -332.95Cr
Net Debt - -
Projected Income Statement - Annual - ADIL PHARPAR
Logo ADIL PHARPAR
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Employees
5
Sector
-
Date Price Change Volume
28/26/28 $5.050 +36.12% 99,654
27/26/27 $3.710 +0.82% 7,357
26/26/26 $3.680 -6.12% 11,696
23/26/23 $3.920 -7.11% 47,359
22/26/22 $4.220 +2.68% 2,269
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ADIL PHARPAR
  1. Stock Market
  2. Stocks
  3. ADIL Stock